vida: extract claims from 2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients.md - Domain: health - Claims: 1, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
This commit is contained in:
Teleo Agents
parent
7a1cc3ba57
commit
67f98106ee
6 changed files with 58 additions and 34 deletions
|
|
@ -1,39 +1,14 @@
|
|||
---
|
||||
description: GLP-1s represent a 63-70 billion dollar market growing to 250-315 billion by 2035 but weight regain after discontinuation means lifelong use and oral formulations at 149 dollars per month will expand the addressable population faster than prices decline
|
||||
type: claim
|
||||
domain: health
|
||||
created: 2026-02-17
|
||||
source: "Grand View Research GLP-1 market analysis 2025; CNBC Lilly/Novo earnings reports; PMC weight regain meta-analyses 2025; KFF Medicare GLP-1 cost modeling; Epic Research discontinuation data"
|
||||
description: GLP-1s represent a 63-70 billion dollar market growing to 250-315 billion by 2035 but weight regain after discontinuation means lifelong use and oral formulations at 149 dollars per month will expand the addressable population faster than prices decline
|
||||
confidence: likely
|
||||
related_claims:
|
||||
- glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms
|
||||
- semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss
|
||||
- indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry
|
||||
- glp1-year-one-persistence-doubled-2021-2024-supply-normalization
|
||||
- glp-1-nutritional-support-advisory-recommends-snap-enrollment-creating-institutional-contradiction-with-snap-cuts
|
||||
- digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes
|
||||
- hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause
|
||||
- uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant
|
||||
- glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation
|
||||
related:
|
||||
- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings
|
||||
- glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints
|
||||
- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months
|
||||
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations
|
||||
- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
|
||||
- semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings
|
||||
reweave_edges:
|
||||
- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31
|
||||
- glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints|related|2026-03-31
|
||||
- glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics|supports|2026-03-31
|
||||
- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04
|
||||
- GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|related|2026-04-04
|
||||
- GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04
|
||||
- semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings|related|2026-04-04
|
||||
- Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|supports|2026-04-17
|
||||
supports:
|
||||
- glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics
|
||||
- Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
|
||||
source: Grand View Research GLP-1 market analysis 2025; CNBC Lilly/Novo earnings reports; PMC weight regain meta-analyses 2025; KFF Medicare GLP-1 cost modeling; Epic Research discontinuation data
|
||||
created: 2026-02-17
|
||||
related_claims: ["glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss", "indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-nutritional-support-advisory-recommends-snap-enrollment-creating-institutional-contradiction-with-snap-cuts", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant", "glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation"]
|
||||
related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations", "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "tirzepatide-patent-thicket-extends-exclusivity-to-2041-bifurcating-glp1-market-into-commodity-and-premium-tiers", "divergence-glp1-economics-chronic-cost-vs-low-persistence"]
|
||||
reweave_edges: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints|related|2026-03-31", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics|supports|2026-03-31", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04", "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|related|2026-04-04", "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability|related|2026-04-04", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings|related|2026-04-04", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|supports|2026-04-17"]
|
||||
supports: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?"]
|
||||
---
|
||||
|
||||
# GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035
|
||||
|
|
@ -186,4 +161,10 @@ Relevant Notes:
|
|||
- [[continuous health monitoring is converging on a multi-layer sensor stack of ambient wearables periodic patches and environmental sensors processed through AI middleware]] -- biometric monitoring could identify GLP-1 candidates earlier and track metabolic response
|
||||
|
||||
Topics:
|
||||
- health and wellness
|
||||
- health and wellness
|
||||
|
||||
## Extending Evidence
|
||||
|
||||
**Source:** eClinicalMedicine meta-analysis, 2025
|
||||
|
||||
Population-level evidence (5.26M patients) of 28-36% AUD risk reduction expands GLP-1 therapeutic scope to behavioral health. Three independent meta-analyses in 2025-2026 converged on similar effect sizes. Neuroimaging confirms reward circuit modulation mechanism. This behavioral health application may alter cost-benefit calculations for chronic GLP-1 use.
|
||||
|
|
|
|||
|
|
@ -88,3 +88,10 @@ EVOKE/EVOKE+ Alzheimer's failure provides critical boundary evidence for GLP-1 C
|
|||
**Source:** Lancet Psychiatry 2026, Karolinska active-comparator cohort
|
||||
|
||||
Swedish national cohort (n=95,490) shows semaglutide reduces depression worsening 44% and anxiety worsening 38% in patients with pre-existing diagnoses, with drug-specific effects (liraglutide 18%, exenatide/dulaglutide no effect). This extends the mesolimbic dopamine modulation mechanism from AUD to mood disorders, suggesting broader psychiatric protective effects beyond substance use.
|
||||
|
||||
|
||||
## Supporting Evidence
|
||||
|
||||
**Source:** eClinicalMedicine meta-analysis, 2025
|
||||
|
||||
Meta-analysis of 5.26M patients across 14 studies shows 28-36% reduction in AUD-related outcomes with neuroimaging confirmation of attenuated alcohol cue reactivity and dopaminergic signaling. Objective biomarkers (PEth, γ-GT) validated behavioral findings. Three independent meta-analyses in 2025-2026 converged on similar effect sizes, indicating robust replication.
|
||||
|
|
|
|||
|
|
@ -25,3 +25,10 @@ A 26-week randomized, double-blind, placebo-controlled trial of 108 patients wit
|
|||
**Source:** Science Media Centre expert reactions, April 30, 2026
|
||||
|
||||
Expert consensus from Science Media Centre reactions confirms SEMALCO trial limitations: (1) single-center design limits generalizability across clinical cultures and patient populations, (2) all participants received CBT alongside semaglutide making it impossible to determine whether the drug works without behavioral co-treatment, (3) population is highly specific - AUD + obesity + treatment-seeking + CBT-receiving, (4) cannot extrapolate to AUD without obesity, non-treatment-seeking populations, or AUD without behavioral support. Prof Matt Field emphasized careful language: 'may help some people' not 'people with AUD' broadly. Experts unanimously called for Phase 3 replication before clinical guideline changes, with no expert claiming this is 'practice-changing' or calling for off-label prescribing despite NNT 4.3.
|
||||
|
||||
|
||||
## Extending Evidence
|
||||
|
||||
**Source:** eClinicalMedicine meta-analysis, 2025
|
||||
|
||||
Meta-analysis demonstrates effect extends beyond comorbid obesity population to general metabolic patients (T2D/obesity) prescribed GLP-1s for metabolic indications, not AUD treatment. This suggests the mechanism is not limited to the obesity-AUD comorbidity subset but operates across metabolic patient populations.
|
||||
|
|
|
|||
|
|
@ -0,0 +1,19 @@
|
|||
---
|
||||
type: claim
|
||||
domain: health
|
||||
description: Population-level evidence from 14 studies shows consistent AUD risk reduction in metabolic patients prescribed GLP-1s for diabetes or obesity, with neuroimaging confirmation of reward circuit modulation
|
||||
confidence: likely
|
||||
source: eClinicalMedicine (The Lancet), meta-analysis of 14 studies (4 RCTs + 10 observational), n=5,262,268
|
||||
created: 2026-05-03
|
||||
title: GLP-1 receptor agonists reduce alcohol use disorder risk by 28-36 percent across diverse populations as demonstrated by meta-analysis of 5.26 million patients
|
||||
agent: vida
|
||||
sourced_from: health/2026-05-03-eclinmed-glp1-alcohol-meta-analysis-5m-patients.md
|
||||
scope: causal
|
||||
sourcer: eClinicalMedicine / The Lancet
|
||||
supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
|
||||
related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
|
||||
---
|
||||
|
||||
# GLP-1 receptor agonists reduce alcohol use disorder risk by 28-36 percent across diverse populations as demonstrated by meta-analysis of 5.26 million patients
|
||||
|
||||
A systematic review and meta-analysis published in eClinicalMedicine synthesized 14 studies (4 RCTs and 10 observational studies) encompassing 5.26 million patients to assess GLP-1 receptor agonist effects on alcohol consumption. The analysis found three convergent signals: (1) AUDIT score reduction of 7.81 points (95% CI −9.02 to −6.60), representing clinically meaningful improvement in alcohol use severity; (2) 36% reduction in alcohol-related events including AUD incidence, recurrence, hospitalizations, and acute intoxication (HR 0.64, 95% CI 0.59–0.69); and (3) 28% lower risk of AUD diagnosis (HR 0.72, 95% CI 0.59–0.89). Semaglutide and liraglutide showed the most consistent effects. Critically, the study population was primarily metabolic patients (T2D/obesity) prescribed GLP-1s for metabolic indications, not treatment-seeking AUD patients. This creates a natural experiment demonstrating real-world effectiveness separate from the treatment-seeking context of SEMALCO. Objective biomarkers confirmed the behavioral findings: PEth (phosphatidylethanol) and γ-GT (gamma-glutamyltransferase) reductions validated reduced alcohol consumption. Neuroimaging studies within the meta-analysis showed attenuated alcohol cue reactivity and dopaminergic signaling with GLP-1 use, providing mechanistic confirmation that GLP-1 modulates reward salience through VTA dopamine pathways, not merely appetite suppression. The high heterogeneity (I² = 87.5%) reflects diverse study designs and populations, but directional consistency across all 14 studies strengthens the finding. Three independent meta-analyses in 2025-2026 converged on similar effect sizes (28-36% risk reduction), indicating rapid field maturation. The convergence of RCT efficacy evidence (SEMALCO) with real-world effectiveness evidence (this meta-analysis) across different populations is unusual for such a new therapeutic application and elevates confidence beyond single-study findings.
|
||||
|
|
@ -45,3 +45,10 @@ The 44% depression worsening reduction in Swedish cohort provides additional evi
|
|||
**Source:** Science Media Centre expert reactions, April 30, 2026
|
||||
|
||||
Dr Marie Spreckley highlighted critical confound: 'All participants received CBT alongside the intervention' making it impossible to determine whether semaglutide works without CBT. The behavioral co-treatment is the unknown variable. This challenges any claim about semaglutide's mechanism in isolation, as the observed effect could be CBT-driven, synergistic, or require CBT as an enabling condition for the dopaminergic mechanism to produce behavioral change.
|
||||
|
||||
|
||||
## Supporting Evidence
|
||||
|
||||
**Source:** eClinicalMedicine meta-analysis, 2025
|
||||
|
||||
Semaglutide showed most consistent effects across 14 studies in meta-analysis of 5.26M patients. AUDIT score reduction of 7.81 points and 28% lower AUD diagnosis risk (HR 0.72) in real-world metabolic patient population, separate from treatment-seeking context.
|
||||
|
|
|
|||
|
|
@ -7,10 +7,13 @@ date: 2025-12-01
|
|||
domain: health
|
||||
secondary_domains: []
|
||||
format: research-article
|
||||
status: unprocessed
|
||||
status: processed
|
||||
processed_by: vida
|
||||
processed_date: 2026-05-03
|
||||
priority: high
|
||||
tags: [GLP-1, semaglutide, alcohol-use-disorder, meta-analysis, systematic-review, population-level, behavioral-health]
|
||||
intake_tier: research-task
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
Loading…
Reference in a new issue